Botulinum toxin A - Merz Pharma
Alternative Names: Bocouture; Incobotulinum toxin A; NT 201L; NT-201; Xeomeen; XEOMIN; Xeomin; Xeomin cosmetic; ZeomaineLatest Information Update: 09 Oct 2024
At a glance
- Originator BIOTECON Therapeutics
- Developer Merz Aesthetics; Merz Pharma; Merz Pharmaceuticals GmbH; Yale University
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Blepharospasm; Dystonia; Glabellar lines; Muscle spasticity; Sialorrhoea; Torticollis
- Phase III Atrial fibrillation; Facial wrinkles
- Phase II Alopecia; Essential tremor; Neuropathic pain; Skin aging; Trigeminal neuralgia
- Phase I Unspecified
- No development reported Pain
- Discontinued Cancer pain
Most Recent Events
- 09 Oct 2024 Phase-II clinical trials in Neuropathic pain in France, Hungary, Spain (SC) (NCT06091020)
- 05 Aug 2024 Pharmacodynamics data from preclinical trial in Neuropathic pain presented at the World Congress of Psychiatry (WCP 2024)
- 14 Jun 2024 Swissmedic approves incobotulinumtoxinA for treatment of lower limb Muscle spasticity in Switzerland